CN102178705A - Anti-cancer medicament taking taxus chinensis essential oil as main raw material - Google Patents
Anti-cancer medicament taking taxus chinensis essential oil as main raw material Download PDFInfo
- Publication number
- CN102178705A CN102178705A CN2011100946058A CN201110094605A CN102178705A CN 102178705 A CN102178705 A CN 102178705A CN 2011100946058 A CN2011100946058 A CN 2011100946058A CN 201110094605 A CN201110094605 A CN 201110094605A CN 102178705 A CN102178705 A CN 102178705A
- Authority
- CN
- China
- Prior art keywords
- ramulus
- cancer
- folium taxi
- taxi cuspidatae
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses an anti-cancer medicament prepared from taxus chinensis essential oil extracted by a physical method. The taxus chinensis essential oil extracted by the physical method is applied to anti-cancer preparations such as capsules, emulsion, suspension, foam agents and the like which are produced in the pharmaceutical industry and are suitable for oral administration directly.
Description
Technical field
The present invention relates to a Ramulus et folium taxi cuspidatae quintessence oil and be applied to treatment for cancer, the particularly treatment of women's gynecological cancer and human hepatocellular, gastric cancer, pulmonary carcinoma.
Background technology
As everyone knows, Ramulus et folium taxi cuspidatae extract paclitaxel has unique antitumaous effect.Especially soft-tissue cancers such as gynecological cancer and human body ear, nose, larynx had unique curative effect.Be one of best cancer therapy drug of the clinical therapeutic efficacy found over nearest more than 20 years. but because of the oral utilization rate of paclitaxel not high, and paclitaxel injection is bigger to the human body side effect, cost an arm and a leg, dosage form is carried shortcomings such as difficult, has increased the difficulty of the autonomous administration of patient.
Summary of the invention
The present invention has overcome the defective of prior art, provide a kind of with the Ramulus et folium taxi cuspidatae quintessence oil be raw material 1, oral 2, external smear type by skin absorbs, act directly on the anticarcinogen of focus.Ramulus et folium taxi cuspidatae quintessence oil involved in the present invention is that the branch and leaf with common various Ramulus et folium taxi cuspidatae are raw material, through cleaning, chopping, going out oil water mixture by high temperature distillation then, through after the condensation, has strong volatile liquid substance with what demixing technology obtained.
With the cancer therapy drug that the Ramulus et folium taxi cuspidatae quintessence oil is made, be divided into oral and external.Oral dosage form is respectively: suspensoid, capsule, emulsus agent etc.The external type is divided into foam, emulsus agent and suspensoid.
The specific embodiment
Implementation method 1 is: oral cancer therapy drug, make suspensoid, capsule, emulsus agent after, directly absorb after oral by the intestines and stomach.After exterior-applied formulation is made foam, emulsus agent and suspensoid, directly smear or be sprayed at lesions position, because of the Ramulus et folium taxi cuspidatae quintessence oil has intensive osmosis, therefore by directly acting on focus after skin or the mucosa absorption.Be mainly used in the various cancers of female breast position and reproductive system, as breast carcinoma, lymphatic cancer, cervical cancer, uterus carcinoma etc.
Directly act on the experimental technique and the result of cancerous cell:
1.1 medicine and reagent
Paclitaxel volatile oil, paclitaxel extract are provided by company.The DMEM culture medium, U.S. sigma company; DMSO, trypsin, U.S. Amresco company; Hyclone, Hangzhou Sijiqing Biological Engineering Material Co., Ltd.; Other reagent are analytical pure, the Beijing Chemical Plant.DMIL HC inverted phase contrast microscope, German Leica company.
1.2 cell strain: HEPG2 (hepatocarcinoma), BGC, A549, SK-OV-3, T-47D, HELA purchase the basis institute in the Chinese Academy of Medical Sciences
2, method
2.1 packet transaction
2.1.1 the antitumor action of paclitaxel volatile oil research
Medicine is pressed the finite concentration preparation with serum-free medium, 0.22 μ m filtering with microporous membrane, and 4 ℃ store for future use.Experiment is divided into blank group, paclitaxel volatile oil variable concentrations processed group (1.25 μ L/mL, 0.6 μ L/mL, 0.5 μ L/mL, 0.4 μ L/mL, 0.35 μ L/mL, 0.3 μ L/mL, 0.15 μ L/mL), positive controls (amycin 10 μ MOL/L); Every group 4 hole, triplicate.
2.2 the cell culture cell is cultivated with the culture medium that contains 10% hyclone, is inoculated in 96 orifice plates in exponential phase, every hole 100 μ L, and cell density is 1*105.2 cultivate 24h in 37 ℃, 5%CO CO2 gas incubator, abandon supernatant, and every hole adds the pastille culture medium, and every hole 100 μ L continue at then and cultivate 48h in the incubator.After 2.3MTT method detects cell survival rate drug effect 48h, abandon supernatant, every hole adds the DMEM culture fluid of 100 μ l and the MTT of 20 μ L 5mg/ml, 37 ℃, 5%CO2 incubator cultivation 4h, abandon supernatant, add DMSO150 μ l, vibration 10min, the trap value (A) in each hole of detection under the 570nm microplate reader.Try to achieve the survival rate of myocardial cell by following formula: survival rate=(respectively organizing cell A/ normal group cell A) * 100%.And the IC50 of calculating medicine.
2.4 statistical procedures
Experimental result adopts SPSS10.0 to carry out statistical procedures.
3, experimental result:
3.1 the Ramulus et folium taxi cuspidatae quintessence oil is tangible dose-effect relationship to HEPG2, T-47D, three kinds of cell inhibiting rates of SK-OV-3, its IC50 is 0.44,0.55,0.381 μ L/ml.
3.2, the Ramulus et folium taxi cuspidatae quintessence oil is tangible dose-effect relationship to Hela, BGC, three kinds of cell inhibiting rates of A549, its IC50 is 0.595,0.587,0.526 μ L/ml.
The cancer therapy drug beneficial effect that this Ramulus et folium taxi cuspidatae quintessence oil is made is:
The bioavailability height, carry easily, convenient drug administration, utilize resource to greatest extent.
Claims (8)
1. cancer therapy drug, the Ramulus et folium taxi cuspidatae quintessence oil that extracts with Ramulus et folium taxi cuspidatae is a raw material, make oral suspensoid, capsule, emulsus agent after, directly absorb and be used for the treatment of cancer by the intestines and stomach; And directly smear or be sprayed at lesions position after making foam, emulsus agent and suspensoid, the principle of topical administration is to utilize the Ramulus et folium taxi cuspidatae quintessence oil to have intensive osmosis, by directly acting on focus after skin or the mucosa absorption, topical administration is mainly used in the various cancers of treatment female breast position and reproductive system, as breast carcinoma, lymphatic cancer, cervical cancer, uterus carcinoma etc.
2. according to the anticarcinogen described in the claim 1, it is characterized in that " utilize the branch and leaf of each kind of taxaceae Taxus; the method for extracting with physics; have strong volatile material: i.e. Ramulus et folium taxi cuspidatae quintessence oil " as primary raw material, be equipped with according to different dosage forms that other material forms by what high temperature distillation got.
3. according to the anticarcinogen described in the claim 1, main administering mode has two kinds: oral and external.Oral reaching by the intestines and stomach absorption utilized purpose, and external is a topical, directly acts on focus by skin and mucosa absorption, is mainly used in treatment women gynecological cancer, as: breast carcinoma, lymphatic cancer, cervical cancer, uterus carcinoma etc.
4. be the anticarcinogen of primary raw material with the Ramulus et folium taxi cuspidatae quintessence oil, dosage form is divided into suspensoid, capsule, Emulsion and foam.Be divided into different dosage forms and different proportioning ratios according to oral with the different modes of administration of external.
5. anticarcinogen according to claim 4, foam mainly passes through physics mode, in the process of spraying, make medicine become cystose, be used to be directly injected to lesions position, as vagina or concealed position such as uterus, cervix uteri, above-mentioned position cancer to the women is carried out topical, directly acts on focus.
6. anticarcinogen according to claim 4, suspensoid are that the Ramulus et folium taxi cuspidatae quintessence oil is incorporated in other edible vegetable oil, make suspensoid, oral or external.According to the difference of administering mode and the ratio difference of proportioning.
7. anticarcinogen according to claim 4, capsule are after the Ramulus et folium taxi cuspidatae quintessence oil is incorporated other edible vegetable oil, and with the edible Gelatinum oxhide parcel, oral administration is used.
8. anticarcinogen according to claim 4, Emulsion are that the Ramulus et folium taxi cuspidatae quintessence oil is incorporated other materials, and oral or topical administration incorporates different materials according to the administering mode difference.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100946058A CN102178705A (en) | 2011-04-15 | 2011-04-15 | Anti-cancer medicament taking taxus chinensis essential oil as main raw material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100946058A CN102178705A (en) | 2011-04-15 | 2011-04-15 | Anti-cancer medicament taking taxus chinensis essential oil as main raw material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102178705A true CN102178705A (en) | 2011-09-14 |
Family
ID=44565111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100946058A Pending CN102178705A (en) | 2011-04-15 | 2011-04-15 | Anti-cancer medicament taking taxus chinensis essential oil as main raw material |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102178705A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335454A (en) * | 2011-09-29 | 2012-02-01 | 胡红节 | Sanitary napkin, toilet paper or care wings containing Taxus chinensis and preparing methods thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101254217A (en) * | 2008-04-14 | 2008-09-03 | 梅州市中大南药发展有限公司 | Preparation of extract of regeneratabl portion of yew and applications of same for preparing oral anti-cancer medicine |
| CN101991516A (en) * | 2009-08-14 | 2011-03-30 | 杨骅力 | Health care cosmetic prepared from raw materials taxus chinensis essential oil and taxus chinensis extracts |
-
2011
- 2011-04-15 CN CN2011100946058A patent/CN102178705A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101254217A (en) * | 2008-04-14 | 2008-09-03 | 梅州市中大南药发展有限公司 | Preparation of extract of regeneratabl portion of yew and applications of same for preparing oral anti-cancer medicine |
| CN101991516A (en) * | 2009-08-14 | 2011-03-30 | 杨骅力 | Health care cosmetic prepared from raw materials taxus chinensis essential oil and taxus chinensis extracts |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335454A (en) * | 2011-09-29 | 2012-02-01 | 胡红节 | Sanitary napkin, toilet paper or care wings containing Taxus chinensis and preparing methods thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768534A (en) | Traditional Chinese medicinal composition with anti-tumor activity | |
| CN103191193A (en) | Traditional chinese medicine extract and preparation method thereof | |
| WO2017092230A1 (en) | Biflavone compound and uses thereof for treating cancers and preparing drugs | |
| CN102178704A (en) | Anti-inflammatory drug prepared from taxus chinensis essential oil and taxus chinensis extract | |
| CN104189110B (en) | A kind of Chinese medicine composition for the treatment of influenza and preparation method thereof | |
| CN103768042A (en) | Application of licochalcone A to prepare anticancer medicines or health-care products | |
| CN102139051B (en) | Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia | |
| CN103405443A (en) | Chinese herbal medicine compound taxus chinensis lipidosome preparation for treating breast cancers and preparation method thereof | |
| CN103735653A (en) | Traditional Chinese medicine extract with anti-tumor activity as well as preparation method and use thereof | |
| CN103393598A (en) | Triptolide liposome preparation for treatment of small cell lung cancer and preparation method thereof | |
| CN102178705A (en) | Anti-cancer medicament taking taxus chinensis essential oil as main raw material | |
| CN104586831A (en) | Application of high-content salvianolic acid B to prepare medicines for resisting cervical carcinoma and preparation method thereof | |
| CN102600180B (en) | Chinese medicinal active ingredient compound preparation for treating breast cancer and lung cancer and preparation method thereof | |
| CN105535003A (en) | Uses of calenduloside E in preparation of anti-tumor medicines | |
| CN102716119A (en) | Novel application of (-)-epigallocatechin gallate in treatment of depression | |
| CN101732340B (en) | Application of ophicalcitum extract and method for preparing same | |
| CN102579528B (en) | Medicine composition for preventing and curing prostatic diseases | |
| CN101974011B (en) | New compound methyl brevicate with medical activity | |
| CN103446193A (en) | Anticancer drug taking Chinese yew essential oil as main raw material | |
| CN109364148A (en) | A kind of FUKE QIANJIN PIAN and preparation method thereof | |
| CN105079005A (en) | Lung cancer and breast cancer treatment compound preparation containing active ingredients of traditional Chinese medicine and preparation method of lung cancer and breast cancer compound preparation | |
| CN104958359A (en) | Compound traditional Chinese medicine preparation and application thereof in treatment of warts and cervical cancer | |
| CN104337844A (en) | Venenum bufonis extractive and application of preparation of venenum bufonis extractive to preparing medicines for treating melanoma | |
| CN104547325A (en) | Medicinal composition for treating chronic idiopathic urticaria and application thereof | |
| CN103751230A (en) | Application of gingko extract nanometer liposome in gynecological disease treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110914 |